Search Results - glioma

7 Results

Sort By:

Bioreducible Poly(beta-amino ester)s for siRNA Delivery

C12218: Efficient Delivery Vehicle for Controlled Gene Knockdown Novelty: This technology comprises the use of bioreducible polymer based nanoparticle system that can release siRNA cargo to the cytoplasm of cells to knockdown target gene expression in tissues. Value Proposition: Gene therapy is a developing medical field and there is a need for...

Published: 5/9/2024 | Inventor(s): Kristen Kozielski, Stephany Tzeng, Jordan Green

Keywords(s): Biologics, Brain Cancer, Cancers, Cell Therapy, Disease Indication, Drug Delivery Vehicle, Glioma, Nucleic Acid, Polymers, Single, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Neurology, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Gene Therapies, Technology Classifications > Therapeutic Modalities > Cell Therapies, Technology Classifications > Therapeutic Modalities > Dendrimers & Polymers, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Oncology > Brain Cancer, Clinical and Disease Specializations > Oncology > Glioma

Nanoparticle Modification of Human Adipose-derived Mesenchymal Stem Cells for Brain Cancer and Other Neurological Diseases

Human Adipose-derived Mesenchymal Stem Cells can be engineered to synthesize and release anti-tumor proteins and therefore can be used as “Trojan Horses”. The inventors have created a novel technology which encompasses a solution containing biodegradable, polymeric nanoparticles that is combined with Freshly-extracted Adipose Tissue (F.A.T.) (from...

Published: 5/9/2024 | Inventor(s): Jordan Green, Alfredo Quinones-Hinojosa

Keywords(s): Biologics, Brain Cancer, Cancers, Cell Therapy, CNS and Neurological Disorders, Disease Indication, Drug Delivery Vehicle, Glioma, Nanoparticles, Single, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type, Whole cell

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Neurology, Technology Classifications > Therapeutic Modalities > Cell Therapies, Technology Classifications > Therapeutic Modalities > Biologics, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Oncology > Brain Cancer, Clinical and Disease Specializations > Oncology > Glioma

M4N and Temozolomide Combination Therapy for Glioblastoma multiforme (GBM)

Unmet NeedGlioblastoma multiforme (GBM) is the most common malignant primary brain tumor in adults and remains one of the most aggressive types of malignancies. The mainstay of GBM treatment is surgery, radiation and adjuvant chemotherapy using temozolomide (TMZ). While treatment options have incrementally improved, survival rates remains dismal. Only...

Published: 5/9/2024 | Inventor(s): Ru Chih Huang, Jong ho Chun, Yu-Ling Lin, Yu-Chuan Liang, Kuang-Wen Liao, Tiffany Jackson, David Mold, Chien-Hsien Lai

Keywords(s): Agonists/Promoters, Brain Cancer, Cancers, Chemotherapy/Immunotherapy, Combination, Disease Indication, Glioblastoma, Glioma, Non-novel, Off-the-shelf, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

Category(s): Technology Classifications > Therapeutic Modalities > Small Molecules, Clinical and Disease Specializations > Oncology > Brain Cancer

Acriflavine Biodegradable CCP:SA Polymers for the Treatment of Malignant Glioma

We investigated the efficacy of the intracranial delivery of a promising anti-cancer drug, whose use has not yet been described for the treatment of malignant glioma. The drug is a trypanocidal, antibacterial, antiviral agent mostly used in cases of sleeping sickness and wound healing. It has demonstrated highly effective antitumor activity against...

Published: 5/9/2024 | Inventor(s): Betty Tyler, Antonella Mangraviti, Henry Brem, Alessandro Olivi, Tula Raghavan

Keywords(s): Brain Cancer, Cancers, Disease Indication, Drug Delivery Mechanism, Drug Delivery Vehicle, Glioma, Non-novel, Polymers, Predicted Novelty, Repurposed, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Neurology, Clinical and Disease Specializations > Oncology > Brain Cancer, Clinical and Disease Specializations > Oncology > Glioma, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities

IDH1 Mutant Glioma Xenograft (JHH-273)

Invention Novelty: A stable, patient-derived IDH- 1 mutant glioma xenograft designed to evaluate potential IDH targeted drug therapies.Value Proposition: IDH-1 (Isocitrate Dehydrogenase) is a very common mutation observed in low-grade glioma tumors. Current IDH-mutated cell lines lack sufficient genetic characteristics similar to human pathologies and...

Published: 5/9/2024 | Inventor(s): Alexandra Borodovsky, Gregory Riggins

Keywords(s): Basic Research Biomarker, Brain Cancer, Cancers, Discovery/Research Tools, Disease Indication, Glioma, In Vivo Research Tool, Mouse Model, Mouse Model Xenograft

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Neurology, Clinical and Disease Specializations > Oncology > Brain Cancer, Clinical and Disease Specializations > Oncology > Glioma, Technology Classifications > Research Tools > Animal Models, Clinical and Disease Specializations > Oncology, Technology Classifications > Research Tools

Glioblastoma Biomarker for Improved Survival Prediction

TITLE: Glioblastoma Biomarker for Improved Survival PredictionCASE NUMBER: C13155UNMET NEEDGlioblastoma GBM), the most common primary brain tumor, has few available therapies providing significant improvement in survival. The median survival of patients after treatment is ~15 months, with only 3-5% surviving longer than 3 years. However, survival varies...

Published: 5/9/2024 | Inventor(s): Patrick Ha, Michael Lim, Chetan Bettegowda, Taeyoung Hwang, Chul-Kee Park, Dimitrios Mathios

Keywords(s): Biomarker, Brain Cancer, Breast Cancer, Cancers, Cervical Cancer, Clinical Diagnostics, Disease Indication, Glioma, In Vitro Diagnostics, Lung Cancer, Prognostic Biomarker

NKCC1-pcDNA3-GFP

Invention novelty: This tangible material is a plasmid vector expressing a NKCC1-EGFP fusion protein. Value Proposition: NKCC1 (Na+-K+-Cl- cotransporter 1) regulates cell volume and accumulation of intracellular Cl- and has been shown to promote invasiveness of brain tumor cells by modulating cell adhesion and cell migration. This vector is a tool that...

Published: 5/9/2024 | Inventor(s): Tomas Garzon-Muvdi, Colette Aprhys, Alfredo Quinones-Hinojosa

Keywords(s): Basic Research Biomarker, Brain Cancer, Cancers, Cell Signaling, Cloning Reagents, Discovery/Research Tools, Disease Indication, Glioblastoma, Glioma, Molecular Switches/Receptors, Plasmid, Recombinant Proteins, Research Reagent

Category(s): Technology Classifications > Research Tools > Proteins, Ligands & Receptors, Technology Classifications > Research Tools > Vectors & Plasmids, Technology Classifications > Research Tools, Clinical and Disease Specializations > Oncology > Brain Cancer